Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
JAZZ PHARMACEUTICALS, INC. v. ROXANE LABORATORIES, INC.
Case Number:
2:10-cv-06108
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
June 19, 2015
Roxane Can Fix Arguments In Jazz's Xyrem Patent Suit
A New Jersey federal judge denied Jazz Pharmaceuticals Inc.'s appeal of an order allowing Roxane Laboratories Inc. to amend its invalidity and noninfringement arguments in a suit over a planned generic of Jazz's narcolepsy drug Xyrem, saying Friday the amendments are timely.
-
June 25, 2014
Drug Challenged Under AIA Biz Method Review For 1st Time
Amneal Pharmaceuticals LLC and others asked the Patent Trial and Appeal Board on Tuesday to invalidate a patent for distribution of Jazz Pharmaceuticals Inc.'s narcolepsy drug Xyrem as an abstract idea, the first time the America Invents Act's business method review program has been used in a drug case.